ClinicalTrials.gg
CompletedNCT00434681Updated Jul 21, 2008

Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.

A Phase 3 interventional study of paracetamol 4.8% paediatric oral suspension in Fever and Pain, sponsored by Sanofi. Completed at 1 site in France. Open to participants aged 1 Day to 8 Years. Per ClinicalTrials.gov, last updated 2008-07-21.

Sponsored by Sanofi · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
1 Day to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing acetaminophen in Fever — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Fever.

Enrollment
23rd of 31
48 · median 100
Started
2006
with 2 others
Phase 3
8 of 31
none open now
Registered
5th of 31
by date

Among the 31 studies testing acetaminophen in Fever, this one is the 23rd largest by enrollment, is one of 3 that started in 2006, is one of 8 in phase 3, and was the 5th registered.

Fever

438 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

1 of the 31 studies testing acetaminophen in Fever is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: 1 Day to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing acetaminophen in Fever, or all of them as a file.
02

Study summary

Evaluate the acceptability over 24 hours of a new paracetamol formulation 4.8% paediatric oral suspension in children weighing between 3 and 26 kg including limits

03

Conditions studied

  • Fever
  • Pain

Browse trials for

04

Who can participate

Ages eligible
1 Day to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Main criteria are listed hereafter :

Inclusion criteria

Inclusion Criteria:

  • Children of both sexes weighing between 3 and 26 kg including limits.
  • With a fever and/or painful episode justifying a paracetamol treatment for a minimum duration of 24 hours.
  • Likely to be followed throughout the entire study period in out-patient.
  • For whom the has been signed by the parents or legal guardian and by the child if old enough (see chapter 12.3).

Exclusion criteria

Exclusion Criteria:

  • Presenting digestive disorders, vomiting.
  • Presenting a to paracetamol or one of the ingredients of the study product
  • Presenting a hepatocellular failure.
  • Presenting a fructose intolerance.
  • Presenting a serious concomitant disease, such as cancer, immune deficiency or a serious renal, hepatic cardiac, neurological, psychiatric or metabolic disease.
  • Presenting a history of significant biological anomalies.
  • Treated with Kayexalate® (sodium polystyrene sulphonate)
  • Not covered by a social security regime.
  • Whose parents are incapable of understanding
  • Who cannot come back to the consultation for the final evaluation and/or submit to the study constraints.
  • Who participated in another clinical study in the 30 days prior to inclusion.
  • Is a relation of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants
06

What researchers measure

Primary outcomes

  1. Acceptability data: Overall evaluation of the treatment by the child's parents or the minder, measured using a semi-quantitative scale with 4 levels (very acceptable, acceptable, indifferent, refusal), for 24 hours (4 evaluations at 6 hour intervals).

  2. Safety data : Events reported by the child, parents or legal guardian during visit 2 ; events compiled in the child's diary ; events recorded by the investigator during Visit 2

Secondary outcomes

  1. Acceptability data: Overall evaluation of the child (from 3 years), using a Hedonic Visual Scale during the last administration prior to Visit V2.

07

Study locations

1 site
  • Sanofi-Aventis
    Paris, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2007
First posted
Feb 13, 2007
Start
Oct 2006
CompletionActual
Apr 2007
Last update
Jul 21, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00434681
Lead sponsor
Sanofi
First posted
Feb 13, 2007
Start date
Oct 2006
Completion
Apr 2007
Last update
Jul 21, 2008

Study contacts

Monique COUDERC, Dr
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion